Literature DB >> 18211793

[Mortality and morbidity in patients with alcohol and biliary-induced acute pancreatitis].

Anders Møller Andersen1, Srdan Novovic, Annette Kjaer Ersbøll, Mark Berner Hansen.   

Abstract

INTRODUCTION: Acute Pancreatitis (AP) is a serious disease with a high mortality. The main aetiological factors involved in development of AP are alcohol and gallstones. Whether aetiology influences mortality and morbidity in AP is not clarified.
MATERIALS AND METHODS: The aim of the present study was to determine if there was a significant difference in mortality in alcohol or biliary-induced AP. We retrospectively analysed data comprising all patients admitted to our department with a first attack of AP registered in a 5-year period (2000-2004).
RESULTS: A total of 290 patients were included. The 30-day and 1-year mortality risks were 5% and 11% and independent of aetiology. ASA-score and severity of AP had a significant effect on the 30-day mortality risk (OR = 9.2 for ASA-score > 2 and OR = 4.2 for severe AP), while daily use of prescribed medicine and ASA-score had a significant effect on the 1-year mortality risk (OR = 10.4 for medicine and OR = 4.5 for ASA-score > 2). Severe AP was a significant predictor for treatment at the Intensive Care Unit (OR = 26.2), as was daily use of prescribed medicine (OR = 7.3).
CONCLUSION: Our data shows that AP is associated with considerable mortality and that there is no significant difference in mortality in relation to alcohol or biliary aetiology.

Entities:  

Mesh:

Year:  2007        PMID: 18211793

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  1 in total

1.  Comparison of clinical characteristics and outcomes between alcohol-induced and gallstone-induced acute pancreatitis: An Australian retrospective observational study.

Authors:  Santiago Cegarra Garcia; Michael Toolis; Max Ubels; Taha Mollah; Eldho Paul; Ashish Pandey; Brandon Thia; Tricia Wong; Ravindranath Tiruvoipati
Journal:  SAGE Open Med       Date:  2021-07-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.